fbpx
Industry Session
SGLT2 inhibitors – the new HF therapies on the block
Saturday July 11, 2020: 7:00PM – 8:30 PM CST (GMT +8)
Subodh-Verma
PROF. SUBODH VERMA
(Canada)
Nikolaus-Marx
PROF. NIKOLAUS MARX
(Germany)
Zieroth-a-espace
DR. SHELLEY ZIEROTH
(Canada)
Chair: Subodh Verma
AGENDA:
  • Welcome and introduction – Subodh Verma
  • A brief history of SGLT2 inhibitors – Subodh Verma
  • What did we learn from CVOTs? A clinical perspective – Nikolaus Marx
  • How might future trials affect how I treat my patients? – Shelley Zieroth
  • Faculty discussion
  • Close – Subodh Verma
  • Live Q&A and discussion
LEARNING OBJECTIVES:
  • Raise awareness of SGLT2 inhibitors as cardiovascular therapies with cardio–renal benefits
  • Highlight appropriate patients for initiation of an SGLT2 inhibitor and share with cardiologists the well-established safety profile and clinical considerations for SGLT2 inhibitor treatment
  • Inform cardiologists of the current evidence and ongoing trials for SGLT2 inhibitors in patients with HF
Looking to register a group of 10 or more? contact: “[email protected]”.

Thank You!